Conversely, a long-term assessment of improved DOR and OS seems more suitable to determine the therapeutic advantage of the drug combination in patients responsive to PARPi, such as in the case of BRCA1/2-mutant or otherwise HR-defective ovarian cancer. Here, BRCA1 is linked to ovarian carcinoma.